Matthew Becker, MD
Interventional Cardiology · Erie, PANPI 1598932550
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $753,329 of the $1,040,566 with a category attached, or 72.4%. 45 manufacturers reported payments, led by Johnson & Johnson at 56.4% of the total. Reporting peaked in 2022 at $233,636 and has fallen 81.5% since, to $43,287 in 2025. Among interventional cardiology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,266 payments — averaging $821.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$587K
- W. L. Gore & Associates, Inc.$116K
- Amgen$109K
- Inari Medical, Inc.$73K
- Esperion Therapeutics, Inc.$43K
- Angiodynamics, Inc.$36K
- plus $75K from 39 others
Across 134 payments — averaging $2046.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$102K
- Contego Medical, Inc$100K
- Abbott$44K
- W. L. Gore & Associates, Inc.$18K
- EKOS Corporation$8K
- Bard Peripheral Vascular, Inc.$2K
- plus $650 from 1 others
What the payments were for
- Consulting fees$156,67315%
- Speaking & faculty fees$753,32972%
- Travel & lodging$65,2516%
- Food & beverage$28,9313%
- Education$80%
- Other$36,3753%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$583,653
- Repatha$107,369
- CT THROMBECTOMY SYSTEM KIT$79,217
- FLOWTRIEVER CATHETER, S$65,419
- NEXLIZET$42,808
- NEXLETOL$42,808
- GORE VIABAHN Endoprosthesis$37,862
- Auryon Laser System 100-120 Vac$36,375
- GORE VIABAHN VBX Balloon Expandable Endo$33,285
- ENTRESTO$32,407
- VIABAHN Endoprosthesis$27,690
- CAMZYOS$15,250
- CARDIOFORM Septal Occluder$11,112
- GORE CARDIOFORM Septal Occluder$9,035
- Product in Development$8,597
- Peripheral Orbital Atherectomy System$7,311
- VIABAHN VBX Balloon Expandable Endoprosthesis$5,461
- Omnilink Elite vascular stent system$4,500
- EXCLUDER AAA Endoprosthesis$4,000
- GORE VIABAHN Endoprosthesis with Heparin$2,627
How this compares
$1,040,566 in reported general payments places this provider in the 95th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 114 | $94,064 |
| JardianceEmpagliflozin | 50 | $41,081 |
| EntrestoSacubitril/Valsartan | 41 | $36,967 |
| Repatha SureclickEvolocumab | 43 | $30,572 |
| EliquisApixaban | 26 | $24,145 |
| VerquvoVericiguat | 28 | $21,268 |
| BrilintaTicagrelor | 32 | $19,862 |
| Ranolazine ErRanolazine | 46 | $3,166 |
| Metoprolol Succinate | 84 | $800 |
| Losartan Potassium | 43 | $632 |
| Atorvastatin Calcium | 63 | $471 |
| ClopidogrelClopidogrel Bisulfate | 58 | $408 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 28 | $390 |
| Amlodipine Besylate | 49 | $216 |
| Rosuvastatin Calcium | 18 | $197 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $587,156 | $94,064114 claims |
| Boehringer IngelheimJardiance | $79 | $41,08150 claims |
| NovartisEntresto | $32,862 | $36,96741 claims |
| PfizerEliquis | $15 | $24,14526 claims |
| MerckVerquvo | $148 | $21,26828 claims |
| AstraZenecaBrilinta | $140 | $19,86232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Erie
- Orestis PappasErie$259K
- Nishant SethiScranton$1.3M
- William GrayWynnewood$753K
- Jon GeorgePhiladelphia$637K
- Shailendra SinghAllentown$470K
- Sanjog KalraPhiladelphia$444K
- James HarveyChambersburg$442K
- Taisei KobayashiPhiladelphia$384K
- Antonis PratsosBroomall$377K
- Ronald FieldsNew Hope$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.